Luye Pharma (HKG:2186) completed a $180 million bond offering, according to a Thursday filing with the Hong Kong bourse.
The debt was offered in the form of 5.25% convertible bonds due 2031, with funds intended for the repurchase of the company's outstanding $180 million 6.25% convertible bonds due 2028.
The repurchase is yet to be completed, the firm said.